Anti-PROTAC Antibody Complexes for Tissue-Specific Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PROTACs face challenges in achieving tissue-specific delivery and have short circulatory half-lives, leading to non-specific degradation and potential side effects, and their low permeability limits cellular entry and efficacy.
Innovation Solution
Development of mono or bi-specific antibodies or antibody fragments that bind to a VHL ligand degrading moiety (degron) of a proteolysis targeting chimera (PROTAC), forming complexes (PAX) without a specific manufacturing step to link PROTACs, allowing targeted delivery and extended half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PROTACs are used for targeted protein degradation, then protein degradation efficacy is improved, but circulatory half-life is short leading to non-specific degradation and side effects
Solution Approach 1:
The patent introduces an antibody as an intermediary carrier that binds to the PROTAC molecule. This antibody-PROTAC complex serves as a mediator that extends the circulatory half-life of the PROTAC while maintaining its protein degradation function. The antibody protects the PROTAC from premature clearance and non-specific degradation, allowing it to reach its target more effectively.
Solution Approach 2:
The patent creates a composite structure by combining the PROTAC molecule with an antibody to form an antibody-PROTAC complex. This composite material leverages the long circulatory half-life and targeted delivery capabilities of the antibody while retaining the protein degradation function of the PROTAC, thus resolving the contradiction between efficacy and duration of action.
2Reliability
If PROTACs are used for protein degradation, then degradation activity is improved, but tissue-specific delivery is poor leading to non-specific effects
Solution Approach 1:
The antibody serves as a targeted delivery intermediary that guides the PROTAC to specific tissues and cells expressing the corresponding antigen. This intermediary function enables tissue-specific delivery while maintaining the PROTAC's degradation activity, reducing non-specific effects.
3Reliability
If PROTACs are used for target protein degradation, then degradation efficacy is improved, but cellular permeability is low limiting entry and efficacy
Solution Approach 1:
The antibody-PROTAC complex uses the antibody as an intermediary that facilitates cellular entry through antigen-mediated endocytosis. This approach overcomes the low cellular permeability of PROTACs while maintaining their degradation efficacy inside the cell.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PAX complexes enhance tissue-specific delivery and pharmacokinetics, enabling efficient degradation of target proteins with improved safety and efficacy profiles.
Implementation Method 1
antibodies, or antibody fragments or fusion proteins thereof, capable of binding to a VHL ligand degrading moiety (degron) of a proteolysis targeting chimera (PROTAC)
Data Source
AI summary
Mono or bi-specific antibodies, antibody fragments, or fusion proteins thereof, are capable of binding to the VHL ligand degrading moiety (degron) of a proteolysis targeting chimera (PROTAC) and, optionally, to a target protein. Complexes (PAX) of such antibodies, antibody fragments, fusion proteins thereof, and PROTACS are also capable of. Methods for their production can be performed, and these antibodies have medical and non-medical uses.